研報掘金丨天風證券:維持信立泰“買入”評級,重點管線進展順利
天風證券研報指出,信立泰(002294.SZ)2024年歸母淨利潤6.02億元,同比增長3.71%,盈利水平穩健提升;2025年第一季度歸母淨利潤爲2億元,同比增長0.03%。製劑驅動營收結構優化,創新產品板塊比重提升。重點管線進展順利:4個項目處於NDA階段:S086的高血壓適應症、恩那度司他(血液透析、腹膜透析CKD患者的貧血適應症)、SAL0108和長效特立帕肽;3個項目處於III期臨牀階段:S086(慢性心衰,已完成入組)、PCSK9 單抗(已完成入組,預計25 年NDA)、SAL0130(一項III 期已完成入組,另一項正在開展入組)。此外,公司積極佈局新領域,逐步將創新藥物研發體系延伸至多肽類和代謝領域。維持“買入”評級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.